Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT03850795 is registered in ClinicalTrials.gov with Hinova Pharmaceuticals USA, Inc. as lead sponsor.

NCT NCT03850795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03850795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Hinova Pharmaceuticals USA, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
March 15, 2021
Completion date
June 28, 2024
Enrollment
104 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, prostate cancer metastatic